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Suppression of immune cell functions is one of the manifestations
of progressive cancer and is a critical factor in the prognosis of
cancer patients (Old, 1981; Hellstrom and Hellstrom, 1991). The
impairments observed in lymphocytes are often subtle as reflected
by variably decreased, but not absent, immune functions and are
more pronounced at the tumour site than in the peripheral circula-
tion of patients with cancer. Evidence indicates that the tumour
itself exerts these immunosuppressive effects, including decreased
monocyte/macrophage functions (Bast and Knapp, 1984) and
diminished cellular immunity as manifested by decreased numbers
of circulating lymphocytes, their reduced responsiveness to mito-
gens and by decreased delayed cutaneous hypersensitivity (DTH)
observed in patients with high tumour burdens (Braun and Harris,
1983; Brooks and Rees, 1988). 
Functional abnormalities in T lymphocytes have been observed
in patients with ovarian, cervical, renal cell, colorectal, prostate
and head and neck cancers, including defective Ca2+ mobilization,
impaired tyrosine kinase activity, and decreased expression of
TcR-associated zeta and epsilon chains (Tartour et al, 1995; Lai 
et al, 1996; Rabinowich et al, 1996; Mulder et al, 1997; deGruijl
et al, 1999; Kuss et al, 1999). In patients with gynaecologic ma-
lignancies, the diminished expression of the signal-transducing
zeta chain has been observed in both tumour-infiltrating T cells
and peripheral blood lymphocytes of patients with advanced -
cancer (Lai et al, 1996; Rabinowich et al, 1996; deGruijl et al,
1999). Decreased expression of CD3-zeta has been correlated with
reduced proliferative responses following antigenic challenge and
reduced cytokine production. Other investigators have correlated
the decreased expression of zeta chain in cancer patients’ 
T-lymphocytes with extent of disease and short survival (Shores 
et al, 1997). 
Investigations into the molecular mechanisms leading to the
reduced zeta expression in advanced ovarian cancer have indicated
that it appeared to result from increased degradation and not from
decreased synthesis (Reichert et al, 1998). In vitro studies of the
mechanism of decreased zeta chain expression have demonstrated
its level could be diminished by direct tumour cell-lymphocyte
contact (Rabinowich et al, 1998). However, evidence for the sys-
temic inhibition of T-cell zeta chain expression has led some
investigators to suggest the presence of a circulating suppressive
factor (Yasumura et al, 1994). The nature of this systemic inhibi-
tion and the role of a putative circulating factor remain undefined. 
While the loss of zeta chain is a common observation, the mech-
anism responsible for the cancer-associated decreased expres-
sion of T-cell zeta chain remains controversial. This study reports
the identification of a circulating factor isolated from ovarian
cancer patients that can mediate suppression of CD3-zeta chains.
Defining the mechanism, through which this factor modulates zeta
chain levels, might ultimately provide a target for the prevention
of the suppressive influences of the tumour microenvironment,
leading to the generation of effective anti-tumor cellular immune
responses and restoration of protective immune responses in
patients with cancer. 
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Summary In women with ovarian cancer, suppression of components of the immune system may promote tumour development. Previous
studies in ovarian cancer have demonstrated that decreased expression and function of the T-cell receptor (TcR)-associated signal
transducing zeta-chain correlates with deficient immune responsiveness of T cells. In this study, sera and ascitic fluids obtained from woman
with advanced ovarian cancer were found to suppress the expression of TcR-associated zeta chain. This suppression of zeta chain
expression was dose-dependent and was not observed with biologic fluids obtained from healthy women.
The factor responsible for the loss of zeta chain was purified from ascites and characterized as a protein with an appropriate molecular
weight of 14 kD. Suppression of T-cell TcR-zeta was specific, since neither lck nor ZAP-70 expression was affected, while zeta chain was
almost completely suppressed. This selective suppression of TcR-zeta expression by the 14 kD ascites-derived factor was shown to operate
at the mRNA level. By defining the mechanism through which this protein modulates TcR-zeta chain levels, it might be possible to ultimately
prevent the suppressive influences of the tumour microenvironment and restor immune competence in patients with ovarian carcinoma.
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MATERIALS AND METHODS 
Patient materials 
Blood specimens and ascitic fluids were obtained from ovarian
cancer patients (n = 30) in the Gynecologic Oncology Clinic of the
Department of Obstetrics and Gynecology of the University of
Louisville School of Medicine. The specimens were collected as
part of an informed consent protocol approved by the University
Human Studies Committee. Blood samples were also obtained
from age-matched normal female volunteers (n = 15) recruited
from patients in the Gynecology Clinic of the Department of
Obstetrics and Gynecology of the University of Louisville School
of Medicine. Blood samples were allowed to clot and then were
centrifuged at 400 g for 10 minutes to sediment cells and clot. The
serum was removed, aliquoted, and stored at –70˚C until analysis. 
Ascitic fluids were also obtained from women with ovarian
cancer (n = 15). Ascitic fluids were initially treated with heparin,
cells and cellular debris were removed by centrifugation and the
fluid was filtered sterile using a 0.45 mm filter. These ascites
samples were aliquoted and stored at –70˚C until analysis. 
Jurkat cells and culture conditions 
To analyse T-cell modulation and activation, Jurkat cells, (Jurkat
E6-1 cells) a human T-cell lymphoma, were used. These
lymphoma cells were obtained from the American Type Culture
Collection (Rockville, MD). They were selected for this study
because they possess a functional TcR/CD3 complex and can be
induced to synthesize and secrete interleukin-2 (IL-2). Jurkat cells
were routinely grown in RPMI 1640 medium supplemented with
10% fetal bovine serum, 0.1 mM nonessential amino acids, 1 mM
sodium pyruvate, 200 mM L-glutamine, 100 mg ml–1 streptomycin
and 100 IU ml–1 penicillin in a humidified 5% CO2 atmosphere.
They were harvested in the log phase of growth and their viability
was evaluated by a trypan blue dye exclusion. All cultures utilized
for this study were >95% viable. 
Western immunoblot assay for lymphocyte protein
expression 
To assess the effects induced by sera or ascitic fluids obtained from
ovarian cancer patients, Jurkat cells (106 cells ml–1) were incubated
in medium supplemented with 0 to 25% patient-derived fluids for 4
days. After 4 days, the cells were centrifuged, the cell pellets washed
and subsequently lysed using 50 mM HEPES, pH 7.2, 150 mM
sodium chloride, 5 mM EDTA, 1 mM sodium-orthovanadate, 2.5%
Triton X-100, 200 mg ml–1 trypsin/chymotrypsin inhibitor, 200 mg
ml–1 chymostatin and 2 mM PMSF. The cell lysate was assayed for
protein by the Bradford Coomassie brilliant blue assay (Bio-Rad
Laboratories, Richmond, CA) and 30 mg of the protein from each
cell lysate was applied per lane to a 15% SDS-PAGE gel. The
proteins were electrophoretically separated by the method of
Laemmli (1970) and transferred to nitrocellulose paper for analysis
by Western immunoblot (Brown et al, 1993). The blots were
blocked with 10% nonfat dry milk and probed overnight at 4˚C in
the same buffer with either mouse anti-CD3-zeta, anti-lck, or anti-
ZAP-70 monoclonal antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA) as the primary antibodies. After this incubation, the
membranes were washed 3 times in 0.1% Tween 20 in TBS for 15
minutes. The blots were then incubated in blocking buffer with
rabbit anti-mouse IgG with horseradish peroxidase (Sigma Chem-
ical Co, St. Louis, MO) for 45 minutes at room temperature. The
immunoblots were washed 3 times in 0.1% Tween 20 in PBS, after
which bound complexes were visualized by enhanced chemilumi-
nescence (ECL, Amersham Life Sciences, Arlington Heights, IL). 
To define the specificity of decreased zeta chain expression,
partially purified zeta suppressor factors (10 ng ml–1) were pre-
pared from the ascites of 5 patients and also from the analogous
fraction from a control serum. Jurkat cells (5 ´ 106 cells) were
incubated with these fractions for 96 hours, the cells were isolated,
and cellular protein expression was examined by Western
immunoblot for the levels of zeta chain as well as of lck and 
ZAP-70 as described above. 
Confirmation of CD3-zeta suppression in normal
lymphocytes 
Blood specimens from healthy donors were also collected to isolate
normal T-lymphocytes. The blood was collected in sterile tubes with
the addition of Heparin (1000 U L–1) and peripheral blood mononu-
clear cells (PMNC) were obtained by density gradient centri-
fugation using Ficol-Hypaque. Further, monocytes/macrophages
were depleted through plastic adherence for 45 minutes at 37˚C to
obtain peripheral blood lymphocytes (PBL). PBL (5 ´ 106 cells)
from 5 normal volunteers were incubated with the partially purified
zeta suppressor factor (10 ng ml–1) for 96 hours. Purified T cells
were isolated by magnetic selection, as previously described (Lai 
et al, 1996). The resulting T-cells, which were >98% CD3+ cells,
were isolated and lysed. The level of CD3-zeta expression was
examined by Western immunoblot, as described above. 
Purification of the zeta suppressive factor 
After the initial studies demonstrated zeta chain suppression in
Jurkat cells incubated in the presence of patients’ sera and ascitic
fluids, further studies were initiated to purify the factor(s) respon-
sible for this effect. The factor inducing suppression of CD3-zeta
was partially purified from 5 patient ascitic fluids known to
contain this activity. Initially, ascitic fluids (250 ml each) were
centrifuged at 400 g for 10 minutes to remove cells and then
filtered through a 500 kD molecular weight (mw) ultrafiltration
membrane. These ascitic fluids were incubated with Affi-Gel Blue
(Bio-Rad Laboratories, Richmond, CA) to remove albumin and
concentrated using a 10 kD mw cutoff ultrafiltration membrane.
This material was then fractionated on the basis of molecular
weight by molecular weight using a Vydac GPC60/150 column
(4.6 ´ 500 mm). The column was run isocratically, using PBS as
the mobile phase. The column was run at 200 ml min–1, monitoring
the elution at 214 nm. The resulting fractions were assayed for the
zeta suppressing activity and the fractions containing this activity
were pooled and further fractionated by reverse phase-HPLC on a
Vydac C8 (300 ml) RP-HPLC column (4.6 ´ 250 mm). The
column was eluted at a flow rate of 1.0 ml min–1 with a linear
gradient of acetonitrile: water: trifluoroacetic acid (0:99.9:0.1 at
time zero to 99.9:0:0.1 at 60 minutes) and 1 minute fractions were
collected. An aliquot of each fraction was assayed for suppression
of zeta chain expression in Jurkat cells. The positive material was
pooled and analysed using MALDI-TOF on a sinapinic acid
matrix by Commonwealth Biotechnologies (Richmond, VA). Identification of ZIP target within the T-cell 
To identify the pathway leading to reduced expression of zeta
chain as defined by Western immunoblot, expression of mRNA 
for zeta chain was examined in Jurkat cells co-incubated with the
factor, as previous described (12). Reverse transcription (RT)
polymerase chain reaction (PCR) was performed under conditions
previously described (Suminami et al, 1995). Jurkat cells (106 cells
ml–1) were incubated with partially purified zeta suppressor factor
(10 ng ml–1) or the analogous fraction from a control serum for 
4 days. Total cellular RNA was then extracted from 106 Jurkat
cells. A hot PCR with [a-32P]dCTP was performed using cDNA
obtained by RT of 100 ng of cellular RNA using sense/antisense
primers: for CD3-zeta chain protein, GTTGCCGATTACAGAG-
GCAC and TTGGTGGCTGTACTAAGACC and for b-action, as
a control, GGGTCAGAAGGATTCCTATG and GGTCTCAAA-
CATGATCTGGG. The amplification was performed by dena-
turing at 94˚C for 60 seconds, annealing at 59˚C for 60 seconds,
and DNA chain extension at 72˚C for 60 seconds. A total of 25
cycles was used for amplification. The amplified products were
then separated on 5% polyacrylamide gels and the radioactive
signals were quantitated using a PhosphorImager SI. The ratio of
the signal for the zeta chain to that for b-action was calculated and
the zeta/action ratios obtained for treated Jurkat cells were
compared with untreated Jurkat cells. 
Statistical analysis 
The reactive bands for zeta expression were quantitated by densit-
ometry and the relative absorbances for these bands were stan-
dardized to a control lane included within each gel. All relative
absorbance determinations were performed at least twice and 
the mean ± standard deviation for each sample was calculated.
Differences between the groups were compared by Student’s t-test
and a two-way ANOVA. For expression of mRNA, the ratio of the
signal for the zeta chain to that for b-action was calculated and the
zeta/actin ratios obtained for treated Jurkat cells were compared
with untreated Jurkat cells. 
RESULTS 
Zeta chain suppression by ovarian cancer-derived
ascitic fluid 
To define the presence of a factor in the ascitic fluids of women
with ovarian cancer, which could modulate TcR-zeta chain levels,
the expression of zeta chains was assessed in Jurkat cells, incu-
bated in media supplemented with 25% ascites for 4 days. The
expression TcR-zeta was evaluated by Western immunoblot and
the representative blots are shown in Figure 1. While suppression
of zeta chain expression was observed in all cases (i.e. with ascitic
fluids from different patients (n = 15)), it was variable, ranging
from 10 to 96% of control zeta levels (72.77 ± 4.98, mean ± SEM).
Zeta chain suppression by cancer sera vs. normal sera 
Since the presence of ascites could diminish the levels of zeta
chain, the presence of similar activity in the sera of these patients
was also evaluated. The modulation of zeta chain expression was
assessed by Western immunoblot in Jurkat cells, incubated in
media supplemented with 25% serum for 4 days. Representative
blots are presented in Figure 2. Zeta chain expression was
suppressed greater than 80% by 27/30 patients’ sera tested. In
contrast, sera from normal volunteers failed to exhibit significant
suppression under the assay conditions. As a control, no signifi-
cant suppression of b-actin levels were observed in Jurkat cells
incubated with patient sera or ascitic fluids. 
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Figure 1 Representative Western immunoblots showing the expression of
CD3 zeta chain in Jurkat cells, following a 4-day incubation with ascitic fluids
(diluted 1:4) obtained from ovarian cancer patients. Control lanes correspond
to Jurkat cells incubated with medium alone 
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Figure 2 Representative Western immunoblots indicating the expression 
of CD3 zeta chain by Jurkat cells, following a 4-day incubation with sera 
(diluted 1:4) obtained from (A) ovarian cancer patients and (B) normal female
volunteers. Control lanes correspond to Jurkat cells incubated with medium
alone. Panel C presents the effect of sera from representative normal
volunteers (N1, N2), cancer patients’ sera (SP1, SP2) and ascites (AP1,
AP2) on the expression of b-actin by Jurkat cells 
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Figure 3 Representative Western immunoblots indicating the expression 
of CD3 zeta chain by Jurkat cells, following a 4-day incubation with 3 sera
(diluted 1:4, 1:10 and 1:20) obtained from women with ovarian cancer. 
The control lane corresponds to T-cell incubated with medium alone Suppression of TcR-zeta in ovarian cancer 1627
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Dose-dependence of zeta suppression 
To determine whether suppression of the zeta expression by body
fluids obtained from women with ovarian carcinoma was dose-
dependent, Jurkat cells were incubated with increasing concen-
trations of serum or ascitic fluids. As Figure 3 illustrates, the
suppression of zeta chain expression was dose-dependent between
5 and 25% of serum added to the culture medium. This observa-
tion was consistent for all 12 patients evaluated. 
Characterization of a patient-derived zeta suppression
factor 
Since the presence and dose-dependence of the zeta chain
suppressing activity were observed in most of the patient-derived
fluids studied, the next step was directed at purification and charac-
terization of the factor responsible for this activity, in terms of
molecular weight, amino acid composition, and sequence. Based
on the zeta chain expression bioassay, the partial purifications of
the factor from the 5 ascitic fluids yielded 3–4 ´ 105-fold purifica-
tions following the final RP-HPLC step. Following partial
purification, this factor was characterized by mass spectrometry.
Determination of the molecular weight of the patient-derived factor
by MALDI-TOF yielded a mass of approximately 14KD (Figure 4).
Analysis of the amino acid composition of this factor verified the
proteinaceous nature of the factor; however, subsequent attempts to
sequence this factor by internal sequencing produced only a single
sequencable peptide ([K,R]TYELYADXLI), which was not signifi-
cantly homologous with known proteins based on BlastP analysis. 
Verification of CD3-zeta suppression in normal
lymphocytes 
The ascites-derived suppressive factors significantly inhibited the
expression of CD3-zeta in Jurkat cells; however, while they may
express many characteristics of normal T-lymphocytes, these
cultured cells are derived from a human T-cell lymphoma and the
observed modulation of CD3-zeta might be an artifact of these 
aberrant cells. The suppression of CD3-zeta chain expression was
analysed by Western immunoblot in normal PBLs, incubated with
zeta inhibitory protein (10 ng ml–1) for 4 days and followed by T-cell
isolation (Figure 5). Using pooled, purified inhibitor, the CD3-zeta
chain expression of normal T-cells was suppressed by an average of
65%; 581.6 ± 107.2 (mean pixels ± SD) for the untreated T-cells
versus 201.2 ± 121.0 for the treated T-cells (P = 0.0079). In contrast,
an analogous fraction from normal serum failed to exhibit signifi-
cant suppression under the assay conditions (data not shown). 
Specificity of suppressive effects 
The serum-mediated suppression of CD3-zeta could be the conse-
quence of a specific suppression of CD3-zeta (or a limited number
of other proteins) or it may represent a non-specific suppression of
total protein synthesis within the T-cell. To explore the selectivity
of the suppression, expressions of 2 TcR-dependent kinases essen-
tial for T-cell activation, lck and ZAP-70, were analysed in addi-
tion to the zeta chain expression following incubation of Jurkat
cells with the partially purified factors from the ascitic fluids of 
5 different ovarian cancer patients. The expression level of each
signalling molecule was compared to its expression level in Jurkat
cells incubated with the analogous fraction obtained from a control
14356.4
Figure 4 MADLI-TOF profile obtained from the ascites-derived suppressor
of CD3-zeta expression 
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Figure 5 Panel A: Western immunoblots indicating the expression of
TcR/CD3 zeta chain by T-lymphocytes obtained from non-tumour bearing
female volunteers, following a 4-day incubation in the presence (+) or
absence (–) of the ascites-derived zeta inhibitory protein (10 ng ml–1). Panel
B: Level of CD3-zeta expression by these normal T-cells determined by
densitometry 
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Figure 6 Western immunoblots indicating the expression of zeta chain
(Panel A), lck (Panel B) and ZAP-70 (Panel C) by Jurkat cells, following a 
4-day incubation with purified ZIP (10 ng ml–1), obtained from 5 women with
ovarian cancer. The control lane corresponds to T-cell incubated with the
analogous fraction from control serum 1628 DD Taylor et al
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serum. Representative data comparing the effects of the factor on
these proteins are presented in Figure 6. Neither lck nor ZAP-70
was suppressed, indicating the effects of zeta inhibitory factor are
not the result of a ubiquitous inhibition of total T-cell proteins or of
an indiscriminate inhibition of proteins within the T-cell activation
pathway. 
Defining the molecular target of ZIP 
The loss of CD3-zeta chain observed in cancer can result from
either increased degradation of the zeta protein or reduced
synthesis of this protein. In our initial study to define the site of
zeta chain suppression, the level of CD3-zeta chain mRNA was
analysed by RT-PCR. The level of specific mRNA was analysed
by 25 cycles of PCR amplification, with b-actin levels used as a
control (Figure 7). T-cells treated with the cancer patient-derived
material exhibited a suppression of mRNA paralleling the loss of
zeta chain protein. 
DISCUSSION 
In women with ovarian cancer, suppression of components of the
immune system frequently occurs and it might facilitate tumour
development. Patients with advanced malignancies exhibit
progressively impaired immune responses, indicating that tumour
cells have developed mechanisms to subvert the immune system
and suppress immune surveillance. Previous studies have demon-
strated that alterations in expression and function of the TcR-
associated signal transducing zeta-chain are responsible for
deficient immune responsiveness of T cells in several types of
malignancies, including ovarian and cervical cancers (Lai et al,
1996; Rabinowich et al, 1996; deGruijl et al, 1999). The decreased
expression of zeta chain in cancer patients’ T lymphocytes has also
been observed to correlate with the extent of disease and short
survival (Shores et al, 1997). While the loss of zeta chain is a
common observation, the mechanisms responsible for the cancer-
associated decreased expression of T-cell zeta chain remain
unknown. 
The zeta chain is responsible for transducing the activation
signal from the antigen binding T-cell receptor to the interior of the
lymphocyte. It has been suggested that the phosphorylation
patterns of the multiple immunoreceptor tyrosine-activation motifs
(ITAMs) of the zeta chains determine the selection of specific 
T-cells during positive and negative selection in the thymus
(Hermans and Malissen, 1993; Irving et al, 1993). Thus, the zeta
chain appears to play a critical role in the development of the TcR
repertoire (Chan et al, 1994). In mature lymphocytes, the absence
of zeta chain alters the expression and functions of CD3/TcR
complex. T-cells with suppressed zeta chain have been demon-
strated to exhibit diminished proliferation and production of
cytokines. Decreased zeta chain expression occurs in other disease
states, including chronic infections and systemic lupus erythe-
matosus, where deficient zeta chain expression has been proposed
to aberrantly modulate T-cell functions (Liossis et al, 1998). 
In this study, we demonstrated that sera and ascitic fluids of
women with advanced ovarian cancer exhibited the ability to
specifically suppress the expression to T-cell CD3-zeta chain
(Figures 1 and 2). Similar suppressive activity could not be
demonstrated in the sera of non-tumour-bearing female controls.
This suppression appeared to decrease zeta chain levels in a dose-
dependent fashion (Figure 3), suggesting that this effect may be
receptor-mediated. These results suggest that the presence of the
zeta inhibitor is associated with the presence of cancer. Recent
preliminary studies have indicated that this factor may be tumour-
derived, since a similar suppressive factor, in terms of activity and
molecular weight, can be demonstrated in conditioned media from
cultured ovarian tumour cells, but not in media from normal
fibroblasts. 
The factor mediating the loss of zeta chain was purified from the
ascites fluids of ovarian cancer patients. This zeta inhibitory
protein (ZIP) has a molecular weight of approximately 14 kDa,
based on mass spectrometry (Figure 4). The suppression of CD3-
zeta mediated by ZIP is not an artifact of the use of Jurkat cells,
since a similar loss of TcR/CD3-zeta was observed in normal
T-cell exposed to purified ZIP. 
The patient-associated suppression of T-cell CD3-zeta appeared
to be the consequence of a specific suppression or loss of zeta
chain expression and not a non-specific suppression of total
protein synthesis within the T-cell, since the TcR-associated
kinases, lck and ZAP-70, were unaffected by exposure to ZIP
(Figure 6), while zeta chain was almost completely suppressed.
This selective suppression of TcR/CD3-zeta appears to be induced
at the level of the zeta mRNA, since T-cells treated with the cancer
patient-derived material exhibited a suppression of mRNA paral-
leling the loss of zeta chain protein (Figure 7). This finding seems
to contradict previous results suggesting that the loss of TcR/CD3-
zeta was due to increased degradation and not decreased synthesis
(Reichert et al, 1998). It should be noted that this previous conclu-
sion was drawn from in vivo derived lymphocytes that have been
exposed to multiple factors within the host, including tumour-
derived proteolytic enzymes and factors capable of inducing
degradative pathways. 
In all of these previous studies addressing tumour-mediated
suppression of TcR/CD3-zeta chain, T-lymphocytes have not been
exposed to a single, purified factor, whether in vivo with exposure
to the tumour-microenvironment or in vitro with exposure to
whole tumour cells. In our initial studies using unfractionated
ascitic fluids, suppression of both CD3-zeta and ZAP-70 and
induction of apoptosis were observed; however, the purified zeta-
inhibitory factor failed to suppress ZAP-70 levels or induce cell
death. Thus, while multiple pathways can lead to suppression of
CD3-zeta either directly or indirectly, it is difficult to define the
contribution of each using unfractionated materials. 
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This study has identified a tumour-associated zeta chain-
inhibitory factor. However, other potential zeta-modulating factors
have been described. In vitro studies on decreased zeta chain
expression have demonstrated a role of surface-associated FasL;
however, several investigators have questioned a pathway by
which cell-associated FasL could induce the systemic loss of CD3-
zeta chains observed in ovarian cancer patients. Our preliminary
findings have demonstrated circulating FasL-associated with shed
tumour membrane vesicles. Similar FasL-containing vesicles have
been shown to be shed by overactivated T-lymphocytes and, in
contrast to soluble FasL, the particulate FasL retains its ability to
mediate activation-induced cell death. Since these vesicles are
greater than 50 million Daltons, they would have been removed
during our presently described purification. In addition, Maccalli
et al (1999) previously demonstrated the modulation of zeta
expression by soluble HLA class I molecules derived from
melanoma cells. The presence of multiple pathways capable of
suppressing the level of TcR/CD3-zeta chains might explain the
apparent less pronounced inhibition of zeta levels with the purified
protein than with the unfractionated ascites. 
The characteristics of these proteins and the mechanism and speci-
ficity of zeta suppression demonstrated in this report suggest that
these factors are distinct. By defining the mechanism through which
our protein modulates TcR/CD3-zeta chain levels, may ultimately
provide a target for the prevention of the suppressive influences of
the tumour microenvironment observed in ovarian cancer. By
preventing T-cell zeta chain loss, effective anti-tumor cellular
immune responses can be generated and protective immune re-
sponses restored. Thus, understanding the molecular mechanisms of
tumour-mediated T-cell dysfunction is likely to have impact on
future developments in the prevention, diagnosis and therapy of
cancer. 
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